Drugs / Denosumab-Ref
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05419427 Comparator | Nov 2021 → Sep 2024 | postmenopausal osteoporosis | Lambda Therapeutic Research Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Denosumab-Ref | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05419427 ↗ |
| Route | Subcutaneous | “Route of Administration-Subcutaneous injection” NCT05419427 ↗ |